Leinco Technologies and CellCarta have announced a strategic collaboration to enhance proteomics solutions aimed at supporting immuno-oncology research and the development of targeted therapies. The partnership brings together complementary expertise in antibody development and advanced protein analysis, with the goal of accelerating biomarker discovery and improving clinical research capabilities.
At the core of the collaboration is the integration of Leinco’s extensive portfolio of high-quality antibodies with CellCarta’s specialized Immuno-MRM (multiple reaction monitoring) assay platform. Leinco’s antibodies are widely used in applications such as immunohistochemistry (IHC) and emerging spatial biology technologies, both of which are critical for studying tissue-specific protein expression. By combining these validated tools with CellCarta’s highly multiplexed and quantitative Immuno-MRM assays, the companies aim to provide a more comprehensive and precise approach to proteomic analysis.
CellCarta’s Immuno-MRM assays enable researchers to measure multiple proteins simultaneously in clinical samples with high sensitivity and specificity. These assays rely on antibodies validated to meet stringent standards established by the Clinical Proteomic Tumor Analysis Consortium (CPTAC), ensuring reliability across various stages of research and clinical trials. The antibody library supporting these assays has been designed to serve a wide spectrum of applications, from early exploratory studies to advanced clinical investigations.
The collaboration is expected to address a growing need for scalable proteomics solutions in both research and clinical settings. Scientists conducting pilot studies can access smaller reagent volumes tailored to discovery-phase work, while clinical laboratories can leverage large-scale reagent supply for routine testing and diagnostics. This flexibility supports a seamless transition from basic research to clinical implementation, an increasingly important requirement in precision medicine.
By enhancing the sensitivity and reproducibility of protein measurements, the partnership aims to facilitate the identification of novel biomarkers and enable more accurate evaluation of therapeutic targets. It also supports monitoring patient responses to treatment, a key factor in advancing personalized medicine approaches.
Both companies believe that the combined platform will significantly accelerate drug development timelines, particularly in immuno-oncology, where understanding complex protein interactions is essential. As targeted therapies continue to reshape cancer treatment, the integration of robust proteomics tools is expected to play a crucial role in improving patient outcomes and driving innovation in the life sciences sector.